Once-Daily Liraglutide Versus Lixisenatide as Add-on to Metformin in Type 2 Diabetes: A 26-Week Randomized Controlled Clinical Trial.

Nauck M, Rizzo M, Johnson A, Bosch-Traberg H, Madsen J, Cariou B

Diabetes care16 Jun 2016Cited by 94 (Europe PMC)

PMID27311491DOI10.2337/dc15-2479PepBankPUB-27311491

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study25

25 results from studies that gave the peptide. 25 results from people.

01HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes on metformin, liraglutide 1.8 mg lowered HbA1c more than lixisenatide 20 µg at week 26.
In plain wordsIn adults with type 2 diabetes, liraglutide lowered HbA1c more than lixisenatide.
Peptide
Liraglutide
Outcome
DecreaseHbA1c change at week 26
Study
n = 404
Comparator
Lixisenatide 20 µg
Analysis
Primary
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1.8 mg · 26 weeksAs given in this study (human).
Measurements
HbA1c treatment difference
−0.62%
liraglutide vs lixisenatide
Source sentences
Summary
liraglutide reduced HbA1c (primary end point) more than lixisenatide (estimated treatment difference -0.62% [95% CI -0.8; -0.4]; P < 0.0001)
1 context sentence(design, population, supporting numbers)
Summary · context
In this 26-week, randomized, parallel-group, open-label trial, 404 patients were randomized 1:1 to liraglutide 1.8 mg or lixisenatide 20 µg as add-on to metformin.
Report a problemFND-2731149101
02HumanRandomized controlled trialEfficacy outcome
In patients with type 2 diabetes on metformin, HbA1c decreased less with lixisenatide than liraglutide; the liraglutide-minus-lixisenatide difference was -0.62% (95% CI -0.8; -0.4).
In plain wordsIn patients with diabetes on metformin, lixisenatide reduced HbA1c less than liraglutide.
Peptide
Lixisenatide
Outcome
IncreaseHbA1c reduction
Study
n = 404
Comparator
Liraglutide 1.8 mg once daily
Analysis
Primary
Outcome group
Glycemic control · Metabolic and weight
Studied dose
20 µg once daily · 26 weeksAs given in this study (human).
Measurements
Treatment difference in HbA1c (liraglutide minus lixisenatide)
−0.62%
week 26, liraglutide 1.8 mg vs lixisenatide 20 µg
95% CI of treatment difference
−0.8 to −0.4%
week 26, liraglutide 1.8 mg vs lixisenatide 20 µg
P value
< 0.0001 unitless
week 26, liraglutide 1.8 mg vs lixisenatide 20 µg
Source sentences
Summary
At week 26, liraglutide reduced HbA1c (primary end point) more than lixisenatide (estimated treatment difference -0.62% [95% CI -0.8; -0.4]; P < 0.0001)
2 context sentences(design, population, supporting numbers)
Summary · context
In this 26-week, randomized, parallel-group, open-label trial, 404 patients were randomized 1:1 to liraglutide 1.8 mg or lixisenatide 20 µg as add-on to metformin.
Summary · context
Lixisenatide was administered once daily within 1 h prior to the morning or evening meal.
Report a problemFND-2731149113
03HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes on metformin, more patients reached HbA1c below 7% with liraglutide than with lixisenatide.
In plain wordsIn adults with type 2 diabetes, more people reached the HbA1c target of 7% with liraglutide than with lixisenatide.
Peptide
Liraglutide
Outcome
IncreasePatients reaching HbA1c <7%
Study
n = 404
Comparator
Lixisenatide 20 µg
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1.8 mg · 26 weeksAs given in this study (human).
Measurements
Patients reaching HbA1c <7%
74.2%
liraglutide
Patients reaching HbA1c <7%
45.5%
lixisenatide
Source sentences
Summary
with more patients reaching HbA1c <7% (53 mmol/mol) and ≤6.5% (48 mmol/mol) versus lixisenatide (74.2% and 54.6% for liraglutide vs. 45.5% and 26.2% for lixisenatide; P < 0.0001 for both).
1 context sentence(design, population, supporting numbers)
Summary · context
In this 26-week, randomized, parallel-group, open-label trial, 404 patients were randomized 1:1 to liraglutide 1.8 mg or lixisenatide 20 µg as add-on to metformin.
Report a problemFND-2731149102
04HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes on metformin, more patients reached HbA1c of 6.5% or less with liraglutide than with lixisenatide.
In plain wordsIn adults with type 2 diabetes, more people reached the stricter HbA1c target of 6.5% with liraglutide than with lixisenatide.
Peptide
Liraglutide
Outcome
IncreasePatients reaching HbA1c ≤6.5%
Study
n = 404
Comparator
Lixisenatide 20 µg
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1.8 mg · 26 weeksAs given in this study (human).
Measurements
Patients reaching HbA1c ≤6.5%
54.6%
liraglutide
Patients reaching HbA1c ≤6.5%
26.2%
lixisenatide
Source sentences
Summary
with more patients reaching HbA1c <7% (53 mmol/mol) and ≤6.5% (48 mmol/mol) versus lixisenatide (74.2% and 54.6% for liraglutide vs. 45.5% and 26.2% for lixisenatide; P < 0.0001 for both).
1 context sentence(design, population, supporting numbers)
Summary · context
In this 26-week, randomized, parallel-group, open-label trial, 404 patients were randomized 1:1 to liraglutide 1.8 mg or lixisenatide 20 µg as add-on to metformin.
Report a problemFND-2731149103
05HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes on metformin, liraglutide lowered fasting plasma glucose more than lixisenatide.
In plain wordsIn adults with type 2 diabetes, liraglutide lowered fasting blood sugar more than lixisenatide.
Peptide
Liraglutide
Outcome
DecreaseFasting plasma glucose change
Study
n = 404
Comparator
Lixisenatide 20 µg
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1.8 mg · 26 weeksAs given in this study (human).
Measurements
Fasting plasma glucose treatment difference
−1.15 mmol/L
liraglutide vs lixisenatide
Source sentences
Summary
Liraglutide reduced fasting plasma glucose more than lixisenatide (estimated treatment difference -1.15 mmol/L [95% CI -1.5; -0.8]; P < 0.0001).
1 context sentence(design, population, supporting numbers)
Summary · context
In this 26-week, randomized, parallel-group, open-label trial, 404 patients were randomized 1:1 to liraglutide 1.8 mg or lixisenatide 20 µg as add-on to metformin.
Report a problemFND-2731149104
06HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes on metformin, liraglutide gave a greater reduction in mean 9-point self-measured plasma glucose than lixisenatide.
In plain wordsIn adults with type 2 diabetes, home-measured blood sugar fell more with liraglutide than with lixisenatide.
Peptide
Liraglutide
Outcome
DecreaseMean 9-point self-measured plasma glucose
Study
n = 404
Comparator
Lixisenatide 20 µg
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1.8 mg · 26 weeksAs given in this study (human).
Source sentences
Summary
Liraglutide provided greater reduction in mean 9-point self-measured plasma glucose (P < 0.0001).
1 context sentence(design, population, supporting numbers)
Summary · context
In this 26-week, randomized, parallel-group, open-label trial, 404 patients were randomized 1:1 to liraglutide 1.8 mg or lixisenatide 20 µg as add-on to metformin.
Report a problemFND-2731149105
07HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes on metformin, postprandial glucose increments were smaller with lixisenatide than with liraglutide for the meal directly after injection, with no differences across all meals.
In plain wordsIn adults with type 2 diabetes, lixisenatide gave smaller blood sugar rises than liraglutide after the meal next to the injection; no difference overall.
Peptide
Liraglutide
Outcome
MixedPostprandial glucose increments
Study
n = 404
Comparator
Lixisenatide 20 µg
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1.8 mg · 26 weeksAs given in this study (human).
Source sentences
Summary
However, postprandial glucose increments were smaller with lixisenatide for the meal directly after injection compared with liraglutide (P < 0.05), with no differences between treatments across all meals.
1 context sentence(design, population, supporting numbers)
Summary · context
In this 26-week, randomized, parallel-group, open-label trial, 404 patients were randomized 1:1 to liraglutide 1.8 mg or lixisenatide 20 µg as add-on to metformin.
Report a problemFND-2731149106
08HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes on metformin, liraglutide and lixisenatide gave similar body weight decreases.
In plain wordsIn adults with type 2 diabetes, liraglutide and lixisenatide led to similar weight loss.
Peptide
Liraglutide
Outcome
No significant changeBody weight change
Study
n = 404
Comparator
Lixisenatide 20 µg
Outcome group
Body weight · Metabolic and weight
Studied dose
1.8 mg · 26 weeksAs given in this study (human).
Measurements
Body weight change
−4.3 kg
liraglutide
Body weight change
−3.7 kg
lixisenatide
Source sentences
Summary
Both drugs promoted similar body weight decrease (-4.3 kg for liraglutide, -3.7 kg for lixisenatide; P = 0.23).
1 context sentence(design, population, supporting numbers)
Summary · context
In this 26-week, randomized, parallel-group, open-label trial, 404 patients were randomized 1:1 to liraglutide 1.8 mg or lixisenatide 20 µg as add-on to metformin.
Report a problemFND-2731149107
09HumanRandomized controlled trialSafety outcome
In adults with type 2 diabetes on metformin, gastrointestinal disorders were the most common adverse events in both liraglutide and lixisenatide groups.
In plain wordsIn adults with type 2 diabetes, stomach and bowel problems were the most common side effects with both liraglutide and lixisenatide.
Peptide
Liraglutide
Outcome
Not applicableGastrointestinal disorders as adverse events
Study
n = 404
Comparator
Lixisenatide 20 µg
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
1.8 mg · 26 weeksAs given in this study (human).
Source sentences
Summary
The most common adverse events in both groups were gastrointestinal disorders.
1 context sentence(design, population, supporting numbers)
Summary · context
In this 26-week, randomized, parallel-group, open-label trial, 404 patients were randomized 1:1 to liraglutide 1.8 mg or lixisenatide 20 µg as add-on to metformin.
Report a problemFND-2731149108
10HumanRandomized controlled trialSafety outcome
In adults with type 2 diabetes on metformin, pulse rose more with liraglutide than with lixisenatide.
In plain wordsIn adults with type 2 diabetes, pulse rate rose more with liraglutide than with lixisenatide.
Peptide
Liraglutide
Outcome
IncreasePulse increase
Study
n = 404
Comparator
Lixisenatide 20 µg
Outcome group
Adverse events · Cardiovascular
Studied dose
1.8 mg · 26 weeksAs given in this study (human).
Source sentences
Summary
Greater increases in pulse, lipase, and amylase were observed with liraglutide.
1 context sentence(design, population, supporting numbers)
Summary · context
In this 26-week, randomized, parallel-group, open-label trial, 404 patients were randomized 1:1 to liraglutide 1.8 mg or lixisenatide 20 µg as add-on to metformin.
Report a problemFND-2731149109
11HumanRandomized controlled trialSafety outcome
In adults with type 2 diabetes on metformin, lipase rose more with liraglutide than with lixisenatide.
In plain wordsIn adults with type 2 diabetes, the pancreatic enzyme lipase rose more with liraglutide than with lixisenatide.
Peptide
Liraglutide
Outcome
IncreaseLipase increase
Study
n = 404
Comparator
Lixisenatide 20 µg
Outcome group
Adverse events · Gastrointestinal
Studied dose
1.8 mg · 26 weeksAs given in this study (human).
Source sentences
Summary
Greater increases in pulse, lipase, and amylase were observed with liraglutide.
1 context sentence(design, population, supporting numbers)
Summary · context
In this 26-week, randomized, parallel-group, open-label trial, 404 patients were randomized 1:1 to liraglutide 1.8 mg or lixisenatide 20 µg as add-on to metformin.
Report a problemFND-2731149110
12HumanRandomized controlled trialSafety outcome
In adults with type 2 diabetes on metformin, amylase rose more with liraglutide than with lixisenatide.
In plain wordsIn adults with type 2 diabetes, the pancreatic enzyme amylase rose more with liraglutide than with lixisenatide.
Peptide
Liraglutide
Outcome
IncreaseAmylase increase
Study
n = 404
Comparator
Lixisenatide 20 µg
Outcome group
Adverse events · Gastrointestinal
Studied dose
1.8 mg · 26 weeksAs given in this study (human).
Source sentences
Summary
Greater increases in pulse, lipase, and amylase were observed with liraglutide.
1 context sentence(design, population, supporting numbers)
Summary · context
In this 26-week, randomized, parallel-group, open-label trial, 404 patients were randomized 1:1 to liraglutide 1.8 mg or lixisenatide 20 µg as add-on to metformin.
Report a problemFND-2731149111
13HumanRandomized controlled trialSafety outcome
In adults with type 2 diabetes on metformin, hypoglycemic episodes were rare and similar between liraglutide and lixisenatide.
In plain wordsIn adults with type 2 diabetes, low blood sugar episodes were rare and similar with liraglutide and lixisenatide.
Peptide
Liraglutide
Outcome
No significant changeHypoglycemic episodes
Study
n = 404
Comparator
Lixisenatide 20 µg
Outcome group
Adverse events · Metabolic and weight
Studied dose
1.8 mg · 26 weeksAs given in this study (human).
Source sentences
Summary
Hypoglycemic episodes were rare and similar between the two treatments.
1 context sentence(design, population, supporting numbers)
Summary · context
In this 26-week, randomized, parallel-group, open-label trial, 404 patients were randomized 1:1 to liraglutide 1.8 mg or lixisenatide 20 µg as add-on to metformin.
Report a problemFND-2731149112
14HumanRandomized controlled trialEfficacy outcome
In patients with type 2 diabetes on metformin, 45.5% reached HbA1c <7% with lixisenatide versus 74.2% with liraglutide (P < 0.0001).
In plain wordsIn patients with diabetes on metformin, fewer reached the lower HbA1c target with lixisenatide than liraglutide.
Peptide
Lixisenatide
Outcome
DecreaseHbA1c below 7% responders
Study
n = 404
Comparator
Liraglutide 1.8 mg once daily
Outcome group
Glycemic control · Metabolic and weight
Studied dose
20 µg once daily · 26 weeksAs given in this study (human).
Measurements
Patients with HbA1c <7%
45.5%
lixisenatide 20 µg, week 26
Patients with HbA1c <7%
74.2%
liraglutide 1.8 mg, week 26
P value
< 0.0001 unitless
HbA1c <7% responders, liraglutide vs lixisenatide
Source sentences
Summary
with more patients reaching HbA1c <7% (53 mmol/mol) and ≤6.5% (48 mmol/mol) versus lixisenatide (74.2% and 54.6% for liraglutide vs. 45.5% and 26.2% for lixisenatide; P < 0.0001 for both).
2 context sentences(design, population, supporting numbers)
Summary · context
In this 26-week, randomized, parallel-group, open-label trial, 404 patients were randomized 1:1 to liraglutide 1.8 mg or lixisenatide 20 µg as add-on to metformin.
Summary · context
Lixisenatide was administered once daily within 1 h prior to the morning or evening meal.
Report a problemFND-2731149114
15HumanRandomized controlled trialEfficacy outcome
In patients with type 2 diabetes on metformin, 26.2% reached HbA1c ≤6.5% with lixisenatide versus 54.6% with liraglutide (P < 0.0001).
In plain wordsIn patients with diabetes on metformin, fewer reached the stricter HbA1c target with lixisenatide than liraglutide.
Peptide
Lixisenatide
Outcome
DecreaseHbA1c at most 6.5% responders
Study
n = 404
Comparator
Liraglutide 1.8 mg once daily
Outcome group
Glycemic control · Metabolic and weight
Studied dose
20 µg once daily · 26 weeksAs given in this study (human).
Measurements
Patients with HbA1c <=6.5%
26.2%
lixisenatide 20 µg, week 26
Patients with HbA1c <=6.5%
54.6%
liraglutide 1.8 mg, week 26
P value
< 0.0001 unitless
HbA1c <=6.5% responders, liraglutide vs lixisenatide
Source sentences
Summary
with more patients reaching HbA1c <7% (53 mmol/mol) and ≤6.5% (48 mmol/mol) versus lixisenatide (74.2% and 54.6% for liraglutide vs. 45.5% and 26.2% for lixisenatide; P < 0.0001 for both).
2 context sentences(design, population, supporting numbers)
Summary · context
In this 26-week, randomized, parallel-group, open-label trial, 404 patients were randomized 1:1 to liraglutide 1.8 mg or lixisenatide 20 µg as add-on to metformin.
Summary · context
Lixisenatide was administered once daily within 1 h prior to the morning or evening meal.
Report a problemFND-2731149115
16HumanRandomized controlled trialEfficacy outcome
In patients with type 2 diabetes on metformin, fasting glucose decreased less with lixisenatide; the liraglutide-minus-lixisenatide difference was -1.15 mmol/L (95% CI -1.5; -0.8).
In plain wordsIn patients with diabetes on metformin, lixisenatide reduced fasting glucose less than liraglutide.
Peptide
Lixisenatide
Outcome
IncreaseFasting plasma glucose reduction
Study
n = 404
Comparator
Liraglutide 1.8 mg once daily
Outcome group
Glycemic control · Metabolic and weight
Studied dose
20 µg once daily · 26 weeksAs given in this study (human).
Measurements
Treatment difference in fasting plasma glucose (liraglutide minus lixisenatide)
−1.15 mmol/L
week 26, liraglutide 1.8 mg vs lixisenatide 20 µg
95% CI of treatment difference
−1.5 to −0.8 mmol/L
week 26, liraglutide 1.8 mg vs lixisenatide 20 µg
P value
< 0.0001 unitless
fasting plasma glucose, liraglutide vs lixisenatide
Source sentences
Summary
Liraglutide reduced fasting plasma glucose more than lixisenatide (estimated treatment difference -1.15 mmol/L [95% CI -1.5; -0.8]; P < 0.0001).
2 context sentences(design, population, supporting numbers)
Summary · context
In this 26-week, randomized, parallel-group, open-label trial, 404 patients were randomized 1:1 to liraglutide 1.8 mg or lixisenatide 20 µg as add-on to metformin.
Summary · context
Lixisenatide was administered once daily within 1 h prior to the morning or evening meal.
Report a problemFND-2731149116
17HumanRandomized controlled trialEfficacy outcome
In patients with type 2 diabetes on metformin, lixisenatide reduced mean 9-point self-measured glucose less than liraglutide (P < 0.0001).
In plain wordsIn patients with diabetes on metformin, lixisenatide reduced average self-measured glucose less than liraglutide.
Peptide
Lixisenatide
Outcome
IncreaseMean 9-point self-measured plasma glucose
Study
n = 404
Comparator
Liraglutide 1.8 mg once daily
Outcome group
Glycemic control · Metabolic and weight
Studied dose
20 µg once daily · 26 weeksAs given in this study (human).
Measurements
P value
< 0.0001 unitless
mean 9-point self-measured plasma glucose, liraglutide vs lixisenatide
Source sentences
Summary
Liraglutide provided greater reduction in mean 9-point self-measured plasma glucose (P < 0.0001).
2 context sentences(design, population, supporting numbers)
Summary · context
In this 26-week, randomized, parallel-group, open-label trial, 404 patients were randomized 1:1 to liraglutide 1.8 mg or lixisenatide 20 µg as add-on to metformin.
Summary · context
Lixisenatide was administered once daily within 1 h prior to the morning or evening meal.
Report a problemFND-2731149117
18HumanRandomized controlled trialEfficacy outcome
In patients with type 2 diabetes on metformin, lixisenatide produced smaller glucose increments after the meal following injection than liraglutide (P < 0.05).
In plain wordsIn patients with diabetes on metformin, glucose rose less after the meal following lixisenatide injection than after liraglutide.
Peptide
Lixisenatide
Outcome
DecreasePostprandial glucose increment after injection
Study
n = 404
Comparator
Liraglutide 1.8 mg once daily
Outcome group
Glycemic control · Metabolic and weight
Studied dose
20 µg once daily · 26 weeksAs given in this study (human).
Measurements
P value
< 0.05 unitless
postprandial glucose increment after the meal directly after injection, lixisenatide vs liraglutide
Source sentences
Summary
However, postprandial glucose increments were smaller with lixisenatide for the meal directly after injection compared with liraglutide (P < 0.05), with no differences between treatments across all meals.
2 context sentences(design, population, supporting numbers)
Summary · context
In this 26-week, randomized, parallel-group, open-label trial, 404 patients were randomized 1:1 to liraglutide 1.8 mg or lixisenatide 20 µg as add-on to metformin.
Summary · context
Lixisenatide was administered once daily within 1 h prior to the morning or evening meal.
Report a problemFND-2731149118
19HumanRandomized controlled trialEfficacy outcome
In patients with type 2 diabetes on metformin, glucose increments across all meals did not differ between lixisenatide and liraglutide.
In plain wordsIn patients with diabetes on metformin, glucose increases across all meals did not differ between lixisenatide and liraglutide.
Peptide
Lixisenatide
Outcome
No significant changePostprandial glucose increments across all meals
Study
n = 404
Comparator
Liraglutide 1.8 mg once daily
Outcome group
Glycemic control · Metabolic and weight
Studied dose
20 µg once daily · 26 weeksAs given in this study (human).
Source sentences
Summary
However, postprandial glucose increments were smaller with lixisenatide for the meal directly after injection compared with liraglutide (P < 0.05), with no differences between treatments across all meals.
2 context sentences(design, population, supporting numbers)
Summary · context
In this 26-week, randomized, parallel-group, open-label trial, 404 patients were randomized 1:1 to liraglutide 1.8 mg or lixisenatide 20 µg as add-on to metformin.
Summary · context
Lixisenatide was administered once daily within 1 h prior to the morning or evening meal.
Report a problemFND-2731149119
20HumanRandomized controlled trialEfficacy outcome
In patients with type 2 diabetes on metformin, weight changed by -3.7 kg with lixisenatide versus -4.3 kg with liraglutide (P = 0.23).
In plain wordsIn patients with diabetes on metformin, weight loss was numerically smaller with lixisenatide than liraglutide, without a significant difference.
Peptide
Lixisenatide
Outcome
No significant changeBody weight change
Study
n = 404
Comparator
Liraglutide 1.8 mg once daily
Outcome group
Body weight · Metabolic and weight
Studied dose
20 µg once daily · 26 weeksAs given in this study (human).
Measurements
Body weight change
−3.7 kg
lixisenatide 20 µg
Body weight change
−4.3 kg
liraglutide 1.8 mg
P value
0.23 unitless
body weight change, liraglutide vs lixisenatide
Source sentences
Summary
Both drugs promoted similar body weight decrease (-4.3 kg for liraglutide, -3.7 kg for lixisenatide; P = 0.23).
2 context sentences(design, population, supporting numbers)
Summary · context
In this 26-week, randomized, parallel-group, open-label trial, 404 patients were randomized 1:1 to liraglutide 1.8 mg or lixisenatide 20 µg as add-on to metformin.
Summary · context
Lixisenatide was administered once daily within 1 h prior to the morning or evening meal.
Report a problemFND-2731149120
21HumanRandomized controlled trialSafety outcome
In patients with type 2 diabetes on metformin, pulse increased less with lixisenatide than liraglutide.
In plain wordsIn patients with diabetes on metformin, pulse increased less with lixisenatide than liraglutide.
Peptide
Lixisenatide
Outcome
DecreasePulse increase
Study
n = 404
Comparator
Liraglutide 1.8 mg once daily
Outcome group
Adverse events · Cardiovascular
Studied dose
20 µg once daily · 26 weeksAs given in this study (human).
Source sentences
Summary
Greater increases in pulse, lipase, and amylase were observed with liraglutide.
2 context sentences(design, population, supporting numbers)
Summary · context
In this 26-week, randomized, parallel-group, open-label trial, 404 patients were randomized 1:1 to liraglutide 1.8 mg or lixisenatide 20 µg as add-on to metformin.
Summary · context
Lixisenatide was administered once daily within 1 h prior to the morning or evening meal.
Report a problemFND-2731149122
22HumanRandomized controlled trialSafety outcome
In patients with type 2 diabetes on metformin, lipase increased less with lixisenatide than liraglutide.
In plain wordsIn patients with diabetes on metformin, lipase increased less with lixisenatide than liraglutide.
Peptide
Lixisenatide
Outcome
DecreaseLipase increase
Study
n = 404
Comparator
Liraglutide 1.8 mg once daily
Outcome group
Adverse events · Gastrointestinal
Studied dose
20 µg once daily · 26 weeksAs given in this study (human).
Source sentences
Summary
Greater increases in pulse, lipase, and amylase were observed with liraglutide.
2 context sentences(design, population, supporting numbers)
Summary · context
In this 26-week, randomized, parallel-group, open-label trial, 404 patients were randomized 1:1 to liraglutide 1.8 mg or lixisenatide 20 µg as add-on to metformin.
Summary · context
Lixisenatide was administered once daily within 1 h prior to the morning or evening meal.
Report a problemFND-2731149123
23HumanRandomized controlled trialSafety outcome
In patients with type 2 diabetes on metformin, amylase increased less with lixisenatide than liraglutide.
In plain wordsIn patients with diabetes on metformin, amylase increased less with lixisenatide than liraglutide.
Peptide
Lixisenatide
Outcome
DecreaseAmylase increase
Study
n = 404
Comparator
Liraglutide 1.8 mg once daily
Outcome group
Adverse events · Gastrointestinal
Studied dose
20 µg once daily · 26 weeksAs given in this study (human).
Source sentences
Summary
Greater increases in pulse, lipase, and amylase were observed with liraglutide.
2 context sentences(design, population, supporting numbers)
Summary · context
In this 26-week, randomized, parallel-group, open-label trial, 404 patients were randomized 1:1 to liraglutide 1.8 mg or lixisenatide 20 µg as add-on to metformin.
Summary · context
Lixisenatide was administered once daily within 1 h prior to the morning or evening meal.
Report a problemFND-2731149124
24HumanRandomized controlled trialSafety outcome
In patients with type 2 diabetes on metformin, hypoglycemic episodes were rare and similar with lixisenatide and liraglutide.
In plain wordsIn patients with diabetes on metformin, low blood sugar episodes were rare and similar with lixisenatide and liraglutide.
Peptide
Lixisenatide
Outcome
No significant changeHypoglycemic episodes
Study
n = 404
Comparator
Liraglutide 1.8 mg once daily
Outcome group
Adverse events · Metabolic and weight
Studied dose
20 µg once daily · 26 weeksAs given in this study (human).
Source sentences
Summary
Hypoglycemic episodes were rare and similar between the two treatments.
2 context sentences(design, population, supporting numbers)
Summary · context
In this 26-week, randomized, parallel-group, open-label trial, 404 patients were randomized 1:1 to liraglutide 1.8 mg or lixisenatide 20 µg as add-on to metformin.
Summary · context
Lixisenatide was administered once daily within 1 h prior to the morning or evening meal.
Report a problemFND-2731149125
25HumanNon-randomized trialSafety outcome
In patients with type 2 diabetes on metformin, gastrointestinal disorders were the most common adverse events during lixisenatide treatment.
In plain wordsIn patients with diabetes on metformin, gastrointestinal disorders were the most common side effects during lixisenatide treatment.
Peptide
Lixisenatide
Outcome
Not applicableGastrointestinal disorders
Study
n: not reported in source
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
20 µg once daily · 26 weeksAs given in this study (human).
Source sentences
Summary
The most common adverse events in both groups were gastrointestinal disorders.
2 context sentences(design, population, supporting numbers)
Summary · context
In this 26-week, randomized, parallel-group, open-label trial, 404 patients were randomized 1:1 to liraglutide 1.8 mg or lixisenatide 20 µg as add-on to metformin.
Summary · context
Lixisenatide was administered once daily within 1 h prior to the morning or evening meal.
Report a problemFND-2731149121

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 4Results postedNCT01973231

Efficacy and Safety of Liraglutide Versus Lixisenatide as add-on to Metformin in Subjects With Type 2 Diabetes

Novo Nordisk A/Sn = 404Oct 2013 to Nov 2014

Diabetes · Diabetes Mellitus, Type 2

Trial page ClinicalTrials.govUpdated 9 Feb 2017

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 4Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 3
27 Oct 2026, 16:36 UTC
Study data updated · source update from Europe PMC
Version 2
12 Oct 2026, 12:10 UTC
Study results updated
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.